Professor Reinier Schlingemann is among the foremost researchers in the fields of ocular angiogenesis, blood-retinal barrier and anti-VEGF therapy in the eye. After receiving his medical degree from the University of Leiden Medical School, Leiden, The Netherlands, Doctor Schlingemann gained his PhD from the University of Nijmegen in 1990, on the subjects of tumor angiogenesis and tumor vascular targeting.
He undertook his residency in ophthalmology at the University of Amsterdam, The Netherlands, followed by a medical retina fellowship with Professor Alan Bird at Moorfields Eye Hospital, London. He is now Professor of Ophthalmology and Medical Retina Specialist at the Amsterdam UMC in Amsterdam, and Director of Research and Invited Professor at the Jules-Gonin Eye Hospital, University of Lausanne .
Professor Schlingemann’s research interests include: the role of growth factors in ocular angiogenesis and fibrosis-particularly in AMD and diabetic retinopathy; the cellular mechanisms underlying loss of the blood-retinal barrier in diabetic retinopathy; and vaso-occlusive mechanisms that cause non-perfusion of the retinal vasculature in diabetic retinopathy. He is also involved in a several prospective clinical trials on the use of anti-angiogenic therapy in AMD, retinal vein occlusion and diabetic retinopathy.
